Published

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2023-09-01
Source: PubMed
DOI: 10.1177/02698811231190865
PubMed: 37572027

Authors

Tagen M Mantuani D van Heerden L Holstein A Klumpers LE Knowles R

Watch author

Derived topics and classifications

psilocybin Receptor Pharmacology Microdosing In Vitro Study Safety In Vitro Study

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.2023-09-01

Related papers

Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-23 Optimizing Microdosing and MeditationClinicalTrials.gov · 2025-06-05